Betrixaban (BioDeep_00000176652)

   

human metabolite blood metabolite


代谢物信息卡片


N-(5-chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide

化学式: C23H22ClN5O3 (451.1411092000001)
中文名称: 贝曲西班
谱图信息: 最多检出来源 Homo sapiens(blood) 2.94%

分子结构信息

SMILES: CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
InChI: InChI=1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)

描述信息

B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AF - Direct factor xa inhibitors
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173067 - Direct Factor Xa Inhibitor
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors
D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins

同义名列表

6 个代谢物同义名

N-(5-chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide; N-(5-Chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide; Betrixaban; PRT 054021; PRT054021; Bevyxxa



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Katarzyna Papaj, Patrycja Spychalska, Patryk Kapica, André Fischer, Jakub Nowak, Maria Bzówka, Manuel Sellner, Markus A Lill, Martin Smieško, Artur Góra. Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease. PloS one. 2022; 17(1):e0262482. doi: 10.1371/journal.pone.0262482. [PMID: 35015795]
  • Amal A El-Masry, Dalia R El-Wasseef, Manal Eid, Ihsan A Shehata, Abdallah M Zeid. Optimization and Validation of a Facile RP-HPLC Method for Determination of Betrixaban and Lercanidipine in Pharmaceutical and Biological Matrices. Journal of chromatographic science. 2021 Aug; 59(8):785-794. doi: 10.1093/chromsci/bmab088. [PMID: 34215884]
  • Kira MacDougall, Alex C Spyropoulos. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. Seminars in respiratory and critical care medicine. 2021 04; 42(2):308-315. doi: 10.1055/s-0041-1723018. [PMID: 33548931]
  • Romain Siriez, Jonathan Evrard, Jean-Michel Dogné, Lionel Pochet, Céline Bouvy, Sarah Lessire, François Mullier, Jonathan Douxfils. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. International journal of laboratory hematology. 2019 Apr; 41(2):250-261. doi: 10.1111/ijlh.12963. [PMID: 30604921]
  • Fakiha Siddiqui, Debra Hoppensteadt, Walter Jeske, Omer Iqbal, Alfonso Tafur, Jawed Fareed. Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2019 Jan; 25(?):1076029619847524. doi: 10.1177/1076029619847524. [PMID: 31088146]
  • Fakiha Siddiqui, Alfonso Tafur, Lorenzo Storino Ramacciotti, Walter Jeske, Debra Hoppensteadt, Eduardo Ramacciotti, Omer Iqbal, Jawed Fareed. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2019 Jan; 25(?):1076029619863493. doi: 10.1177/1076029619863493. [PMID: 31298056]
  • Gerald Chi, C Michael Gibson, Yuyin Liu, Adrian F Hernandez, Russell D Hull, Alexander T Cohen, Robert A Harrington, Samuel Z Goldhaber. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. American journal of hematology. 2019 01; 94(1):21-28. doi: 10.1002/ajh.25296. [PMID: 30252149]
  • Romain Siriez, Jonathan Evrard, Jean-Michel Dogné, Lionel Pochet, Damien Gheldof, Bernard Chatelain, François Mullier, Jonathan Douxfils. Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide. Thrombosis and haemostasis. 2018 Jul; 118(7):1203-1214. doi: 10.1055/s-0038-1657772. [PMID: 29890519]
  • C Michael Gibson, Rim Halaby, Serge Korjian, Yazan Daaboul, Douglas F Arbetter, Megan K Yee, Samuel Z Goldhaber, Russel Hull, Adrian F Hernandez, Shiao-Ping Lu, Olga Bandman, Janet M Leeds, Alex Gold, Robert A Harrington, Alexander T Cohen. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. American heart journal. 2017 Mar; 185(?):93-100. doi: 10.1016/j.ahj.2016.12.004. [PMID: 28267480]
  • Alexander T Cohen, Robert A Harrington, Samuel Z Goldhaber, Russell D Hull, Brian L Wiens, Alex Gold, Adrian F Hernandez, C Michael Gibson. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. The New England journal of medicine. 2016 08; 375(6):534-44. doi: 10.1056/nejmoa1601747. [PMID: 27232649]
  • Meyer Michel Samama, Sadia Meddahi, Charles Marc Samama. Pharmacology and laboratory testing of the oral Xa inhibitors. Clinics in laboratory medicine. 2014 Sep; 34(3):503-17. doi: 10.1016/j.cll.2014.06.009. [PMID: 25168939]
  • Genmin Lu, Francis R DeGuzman, Stanley J Hollenbach, Mark J Karbarz, Keith Abe, Gail Lee, Peng Luan, Athiwat Hutchaleelaha, Mayuko Inagaki, Pamela B Conley, David R Phillips, Uma Sinha. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature medicine. 2013 Apr; 19(4):446-51. doi: 10.1038/nm.3102. [PMID: 23455714]
  • Joel Morganroth, Daniel D Gretler, Stanley J Hollenbach, Joseph L Lambing, Uma Sinha. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study. Expert opinion on pharmacotherapy. 2013 Jan; 14(1):5-13. doi: 10.1517/14656566.2013.753057. [PMID: 23216423]
  • Birgitte Klindt Poulsen, Erik Lerkevang Grove, Steen Elkjaer Husted. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012 Sep; 72(13):1739-53. doi: 10.2165/11635730-000000000-00000. [PMID: 22931521]
  • Jason Morell, Bridgette Sullivan, Marina Khalabuda, Brian F McBride. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. Journal of clinical pharmacology. 2010 Sep; 50(9):986-1000. doi: 10.1177/0091270009355814. [PMID: 20124518]